文献速递重症综合管理与镇静镇痛

苯磺酸瑞马唑仑与丙泊酚用于ICU短期轻镇静(SHOSREB):多中心、随机、单盲、对照试验

Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial.
PubMed 文献 · Intensive Care Med · 2026-03-31
一句话结论在需要轻镇静(RASS -2至+1)的机械通气ICU患者中,苯磺酸瑞马唑仑短期镇静成功率不劣于丙泊酚(两组均97.5%)。

该多中心、随机、单盲、非劣效性试验纳入164例需要轻镇静(RASS -2至+1)的机械通气患者,等比例随机分为苯磺酸瑞马唑仑组和丙泊酚组。主要终点为成功镇静,即研究药物输注期间未给予抢救镇静药且至少70%的总输注时间维持RASS -2至+1。两组成功镇静比例均为97.5%(差值0,95%CI -6.5%至6.4%,高于预设非劣效界值-8%),目标RASS时间百分比无显著差异(瑞马唑仑组88.6% vs 丙泊酚组89.4%,p=0.543)。结论认为苯磺酸瑞马唑仑在ICU短期轻镇静方面不劣于丙泊酚。

要点

  • 在需要轻镇静(RASS -2至+1)的机械通气ICU患者中,苯磺酸瑞马唑仑组成功镇静比例为97.5%,丙泊酚组也为97.5%,差值0(95%CI -6.5%至6.4%),高于非劣效界值-8%。
  • 瑞马唑仑中位维持剂量为0.20 [0.19-0.30] mg·kg⁻¹·h⁻¹,丙泊酚为0.61 [0.30-1.17] mg·kg⁻¹·h⁻¹,两组中位输注时长分别为10.5 [8.1-14.7] h和11.0 [7.0-14.3] h(p=0.534)。
  • 瑞马唑仑组目标RASS时间百分比为88.6%(95%CI 84.2%-92.9%),丙泊酚组为89.4%(95%CI 85.0%-93.8%),组间无显著差异(p=0.543)。
  • 该研究为多中心、随机、单盲、非劣效性试验,样本量164例,等比例随机分组。

适用人群与场景

  • 需要轻镇静的机械通气ICU患者,轻镇静定义为RASS评分在-2至+1之间。

诊断标准与关键阈值

  • 轻镇静目标:Richmond Agitation-Sedation Scale(RASS)评分在-2至+1之间。
  • 成功镇静定义:研究药物输注期间未给予抢救镇静药,且维持RASS评分在-2至+1至少占总共输注时间的70%。
  • 非劣效界值:-8%。

处置流程与药物剂量

  • 苯磺酸瑞马唑仑持续输注中位维持剂量0.20 [0.19-0.30] mg·kg⁻¹·h⁻¹,中位输注时长10.5 [8.1-14.7] h。
  • 丙泊酚持续输注中位维持剂量0.61 [0.30-1.17] mg·kg⁻¹·h⁻¹,中位输注时长11.0 [7.0-14.3] h。

研究设计与关键结果

  • 多中心、随机、单盲、非劣效性试验,共纳入164例机械通气需要轻镇静的ICU患者,等比例随机分为苯磺酸瑞马唑仑组和丙泊酚组。
  • 两组成功镇静比例均为97.5%(p=0.497),差值0(95%CI -6.5%至6.4%),高于预设非劣效界值-8%。
  • 瑞马唑仑组目标RASS时间百分比88.6%(95%CI 84.2%-92.9%),丙泊酚组89.4%(95%CI 85.0%-93.8%),组间无显著差异(p=0.543)。
  • 瑞马唑仑中位维持剂量0.20 [0.19-0.30] mg·kg⁻¹·h⁻¹,丙泊酚0.61 [0.30-1.17] mg·kg⁻¹·h⁻¹;中位输注时长分别为10.5 [8.1-14.7] h和11.0 [7.0-14.3] h(p=0.534)。

证据类型、等级与局限

  • 证据类型:多中心、随机、单盲、非劣效性对照试验。
  • 结论:苯磺酸瑞马唑仑在实现ICU短期轻镇静方面可能不劣于丙泊酚。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于需要短期轻镇静(RASS -2至+1)的机械通气ICU患者,苯磺酸瑞马唑仑可作为丙泊酚之外的一种选择,其成功镇静率不劣于丙泊酚。
  • 使用苯磺酸瑞马唑仑时参考本试验中位维持剂量0.20 [0.19-0.30] mg·kg⁻¹·h⁻¹持续输注,中位时长10.5 [8.1-14.7] h。

指南或共识出处

  • SHOSREB试验,ClinicalTrials.gov注册号NCT05782894,注册日期2023年2月18日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To explore the efficacy and safety of remimazolam besylate in short-term sedation in the ICU in comparison with propofol.

METHOD: A multicenter, randomized, single-blind, non-inferiority trial was conducted in mechanically ventilated patients, who needed light sedation, defined as Richmond Agitation-Sedation Scale (RASS) scores between -2 and + 1. The primary outcome was successful sedation, which was defined as no rescue sedative administered during the study drug infusion period while maintaining RASS scores between -2 and + 1 for at least 70% of the total infusion time.

RESULTS: A total of 164 participants were included and randomized equally into the remimazolam group and the propofol group. Remimazolam was continuously infused for 10.5 [8.1-14.7] h and propofol for 11.0 [7.0-14.3] h (p = 0.534). The median average maintaining dose of remimazolam and propofol was 0.20 [0.19-0.30] mg·kg⁻1·h⁻1 and 0.61 [0.30-1.17] mg·kg⁻1·h⁻1, respectively. The percentage of participants successfully sedated in both groups was 97.5% (p = 0.497) with a difference of 0 (95% confidence interval (CI) -6.5% to 6.4%), above the predefined non-inferiority margin of -8%. There was no significant difference in the mean percentage of time with target RASS scores between the remimazolam group (88.6%; 95% CI: 84.2%-92.9%) and the propofol group (89.4%; 95% CI: 85.0%-93.8%) (p = 0.543).

CONCLUSION: Remimazolam besylate could be non-inferior to propofol for achieving successful short-term light sedation in the ICU.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05782894 on Feb 18th, 2023.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Yang X, Pan J, Gong X, et al. Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial. Intensive Care Med. 2026. PMID: 41915173. doi:10.1007/s00134-026-08381-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。